Within the different monocyte subsets, the cell surface CD14 MFI was decreased on CD14+/CD16− and CD14+/CD16+ monocytes from patients with fast progressing ALS compared with slowly progressing patients with ALS (p < 0.01) and HC (p < 0.01) (Fig. 3D). This evidence concerns the gene CD14 and amyotrophic lateral sclerosis.